15- methyl- 8- aza- 16- oxagona- 1,3,5(10),13- tetraen- 17- one (MAOTO)

01/01/2017 - "We previously reported in randomized controlled trials that maoto, a traditional herbal medicine, showed clinical and virological efficacy for seasonal influenza. "
01/01/2017 - "The present study provides evidence that supports the clinical use of maoto for the treatment of influenza."
01/01/2017 - "In this study, a culturing system for influenza was used to test the effect of maoto. "
01/01/2021 - "Association between Maoto Use and Hospitalization for Seasonal Influenza in a Nonelderly Cohort in Japan."
08/01/2012 - "The herbal medicine, maoto, has been traditionally prescribed to patients with influenza in Japan. "

01/01/2014 - "This study was conducted to evaluate the alleviative effects of maoto against early phase of influenza virus infection and its preliminary mode of actions through immune systems. "
01/01/2021 - "On the fifth day of oral administration to mice intranasally infected with influenza virus [A/PR/8/34 (H1N1)], maoto significantly improved survival rate, decreased viral titer, and ameliorated the infection-induced phenotype as compared with control mice. "
02/05/2019 - "We previously reported that the Japanese Kampo medicine maoto ameliorated flu-like symptoms in a rat infection model and dynamically changed plasma metabolites as indicated by metabolome analysis. "
01/01/2021 - "In this study, we evaluated the effects of maoto as an herbal multi-compound medicine on host responses in a mouse model of influenza infection. "
07/01/2022 - "Oral administration of maoto is suggested to be effective as PEP against nosocomial COVID-19 infection."

03/18/2019 - "Although we could not reach a definitive conclusion because of the small sample sizes and high risk of bias in the analysed studies, maoto may lower the duration of fever when it is used alone or in combination with NAIs and may be a well-tolerated treatment. "
03/18/2019 - "We found that maoto plus NAIs was superior to NAIs alone in terms of the duration of fever in one RCT (P < 0.05, median difference = - 6 h) and four NRSs (P = 0.003, weighted mean difference = - 5.34 h). "
08/01/2012 - "Median durations of fever of patients assigned maoto, oseltamivir, or zanamivir were 29, 46, or 27 h, respectively, significantly different for maoto and oseltamivir. "
08/01/2012 - "The data of 28 patients randomly assigned to maoto (n = 10), oseltamivir (n = 8), or zanamivir (n = 10) were analyzed for the duration of fever (>37.5°C) and total symptom score from symptom cards recorded by the patient. "

01/01/2014 - "However, the efficacy of maoto against the virus infection remains to be elucidated. "
06/01/2009 - "A traditional Chinese herbal medicine, Kampo medicine, maoto, has been widely used in the treatment of febrile symptoms caused by viral infection. "

07/01/2022 - "Maoto, a traditional herbal medicine, for post-exposure prophylaxis for Japanese healthcare workers exposed to COVID-19: A single center study."
07/01/2022 - "During the observation period of 1 week, significantly fewer subjects were diagnosed with COVID-19 in the maoto group (N = 3, 7.1%) than in the control group (N = 6, 46.2%). "
01/01/2022 - "Based on the results, we believe that the use of Maoto among Kampo formulas is suitable as a countermeasure against COVID-19."
07/01/2022 - "This study was done to determine if maoto, a traditional herbal medicine commonly used for diseases with symptoms similar to those of COVID-19, can be repurposed for post-exposure prophylaxis to prevent the spread of nosocomial infection with SARS-CoV-2. "
07/01/2022 - "Oral administration of maoto is suggested to be effective as PEP against nosocomial COVID-19 infection."